Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026

What happened: Spyre Therapeutics (NASDAQ: SYRE) announced clinical and preclinical data presentations at United European Gastroenterology Week 2026 in Barcelona, including the first congress presentation of clinical data across its three IBD antibodies SPY001, SPY002, and SPY003, now tested as monotherapies and pairwise Why it matters: Silvio Danese, Chair of the SKYLINE trial Steering Committee, said clinical proof-of-concept is now demonstrated across all three antibodies, and combination results are expected next year with the potential to raise the therapeutic ceiling for IBD patients. Market: -0.2% today ($79.90), +161.3% YTD, 0.9x vol — as of 22:46 UTC

Spyre Therapeutics (NASDAQ: SYRE) announced clinical and preclinical data presentations at United European Gastroenterology Week 2026 in Barcelona, including the first congress presentation of clinical data across its three IBD antibodies SPY001, SPY002, and SPY003, now tested as monotherapies and pairwise

Silvio Danese, Chair of the SKYLINE trial Steering Committee, said clinical proof-of-concept is now demonstrated across all three antibodies, and combination results are expected next year with the potential to raise the therapeutic ceiling for IBD patients. Market: -0.2% today ($79.90), +161.3% YTD, 0.9x vol — as of 22:46 UTC